GUARD Consortium shared a post on X:
“Who is REINFORCE designed for?
Patients with mHSPC treated with Apalutamide + ADT who do not achieve a deep PSA response following initial treatment.
A precise definition to identify those most likely to benefit from treatment intensification.”
Other articles about GU Oncology on OncoDaily.